We are live on ! Find out more
SCM

Squadron Capital Management Portfolio holdings

AUM $322M
This Fund
S&P 500
This Quarter Est. Return
+39.23%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$273M
AUM Growth
+$36.9M
Cap. Flow
+$14.1M
Cap. Flow %
5.18%
Top 10 Hldgs %
67.07%
Holding
52
New
19
Increased
8
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$9.38M
2
ANL
Adlai Nortye
ANL
+$8.46M
3
RLMD icon
Relmada Therapeutics
RLMD
+$8.4M
4
NKTR icon
Nektar Therapeutics
NKTR
+$7.12M
5
RLAY icon
Relay Therapeutics
RLAY
+$6.02M

Top Sells

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$10.3M
2
TERN
Terns Pharmaceuticals
TERN
+$7.68M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$6.55M
4
UPB
Upstream Bio Inc
UPB
+$6.26M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$4.73M

Sector Composition

Rank Sector Weight
1 Healthcare 91.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
1
Relmada Therapeutics
RLMD
$512M
$59M 21.61%
8,474,571
+1,774,571
+26% +$8.4M
COGT icon
2
Cogent Biosciences
COGT
$6.58B
$30.3M 11.11%
787,492
+7,492
+1% +$277K
KALV
3
DELISTED
KalVista Pharmaceuticals
KALV
$19.8M 7.27%
985,100
+285,100
+41% +$4.6M
KOD icon
4
Kodiak Sciences
KOD
$2.59B
$14.5M 5.31%
380,000
+88,290
+30% +$2.28M
ABVX
5
Abivax
ABVX
$10.4B
$14.5M 5.3%
130,000
-15,000
-10% -$1.78M
EWTX icon
6
Edgewise Therapeutics
EWTX
$4.8B
$11M 4.04%
350,000
– –
NKTR icon
7
Nektar Therapeutics
NKTR
$2.47B
$8.99M 3.3%
+125,000
New +$7.12M
ANL
8
Adlai Nortye
ANL
$853M
$8.76M 3.21%
+1,265,231
New +$8.46M
ZNTL icon
9
Zentalis Pharmaceuticals
ZNTL
$255M
$8.5M 3.11%
+3,631,000
New +$9.38M
MAZE
10
Maze Therapeutics
MAZE
$1.51B
$7.69M 2.82%
257,500
-232,500
-47% -$10.3M
SCYX icon
11
SCYNEXIS
SCYX
$51.5M
$6.98M 2.56%
+951,087
New +$5.88M
RLAY icon
12
Relay Therapeutics
RLAY
$4.35B
$6.69M 2.45%
+672,500
New +$6.02M
KALV
13
CALL
DELISTED
KalVista Pharmaceuticals
KALV
$6.34M 2.32%
+315,000
New +$5.08M
CCCC icon
14
C4 Therapeutics
CCCC
$522M
$5.92M 2.17%
+2,250,000
New +$5.3M
IKT icon
15
Inhibikase Therapeutics
IKT
$378M
$5.88M 2.15%
3,500,000
-725,000
-17% -$1.29M
PALI icon
16
Palisade Bio
PALI
$373M
$5.25M 1.92%
3,000,000
-1,500,000
-33% -$2.73M
EPRX
17
Eupraxia Pharmaceuticals
EPRX
$439M
$4.92M 1.8%
680,000
+180,000
+36% +$1.45M
GHRS icon
18
GH Research
GHRS
$2.02B
$4.57M 1.67%
325,000
+10,000
+3% +$153K
KPTI icon
19
PUT
Karyopharm Therapeutics
KPTI
$45.8M
$4.18M 1.53%
+750,000
New +$5.72M
PMN icon
20
ProMIS Neurosciences
PMN
$133M
$4.13M 1.51%
+324,977
New +$4.85M
IDYA icon
21
PUT
IDEAYA Biosciences
IDYA
$3.49B
$4M 1.47%
+120,000
New +$4.03M
LPCN icon
22
Lipocine
LPCN
$17.4M
$3.6M 1.32%
450,000
-80,000
-15% -$697K
IDYA icon
23
CALL
IDEAYA Biosciences
IDYA
$3.49B
$3.48M 1.27%
+104,300
New +$3.5M
IVA
24
Inventiva
IVA
$1.09B
$2.97M 1.09%
535,000
+235,000
+78% +$1.43M
ALXO icon
25
ALX Oncology
ALXO
$271M
$2.93M 1.07%
+1,460,000
New +$2.78M
1
2 3

Similar funds

BCP
Bayberry Capital Partners New York $323M AUM 27.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
ECH
ER Collective Holdings Washington, District of Columbia $326M AUM
BCM
Boone Capital Management Atlanta, Georgia $326M AUM 86.31% 1-Year Est. Return
KI
Keewaydin Investments Southampton, New York $317M AUM
GWM
Graybill Wealth Management Elmhurst, Illinois $328M AUM 21.42% 1-Year Est. Return
KC
KHIS Custodian Dallas, Texas $316M AUM
HNH
Hopwood Nicholas Hunter $315M AUM

Squadron Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Squadron Capital Management held 52 positions worth $273M, up 16% from $236M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Squadron Capital Management deployed $14.1M of net new capital in Q1 2026, opening 19 new positions and adding to 8 existing holdings. Its largest new stake was Zentalis Pharmaceuticals: 3,631,000 shares worth $8.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier.

On the sell side, the largest reduction was Maze Therapeutics, an estimated $10.3M trimmed.

  • Squadron Capital Management's largest Q1 2026 buy was Zentalis Pharmaceuticals: 3,631,000 shares worth $8.5M.
  • Squadron Capital Management added most to Relmada Therapeutics in Q1 2026, an estimated $8.4M increase.
  • Squadron Capital Management's biggest Q1 2026 reduction was Maze Therapeutics, cutting an estimated $10.3M.
  • Squadron Capital Management fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $7.68M.
  • Squadron Capital Management's ten largest holdings make up 67% of its $273M portfolio in Q1 2026.
  • Squadron Capital Management opened 19 new positions and closed 15 in Q1 2026.
  • Squadron Capital Management's portfolio value rose 16% quarter-over-quarter to $273M.

Based on Squadron Capital Management's 13F filing for Q1 2026, filed 15 May 2026.